{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:09:30Z","timestamp":1784740170396,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100019971","name":"Dr. Marnie Rose Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019971","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s11060-022-04144-y","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T17:36:07Z","timestamp":1665077767000},"page":"221-231","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab"],"prefix":"10.1007","volume":"160","author":[{"given":"Guangrong","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayank","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Linendoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Maximilian","family":"Buja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi B.","family":"Bhattacharjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leomar Y.","family":"Ballester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Pilichowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian K.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgene W.","family":"Hergenroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Williams F.","family":"Glass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongzhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K.","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4635-0914","authenticated-orcid":false,"given":"Jay-Jiguang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,6]]},"reference":[{"key":"4144_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996","journal-title":"N Engl J Med"},{"key":"4144_CR2","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12967-018-1507-6","volume":"16","author":"LM Liau","year":"2018","unstructured":"Liau LM, Ashkan K, Tran DD et al (2018) First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med 16:142","journal-title":"J Transl Med"},{"key":"4144_CR3","doi-asserted-by":"publisher","first-page":"44015","DOI":"10.18632\/oncotarget.17054","volume":"8","author":"P Zhu","year":"2017","unstructured":"Zhu P, Du XL, Lu G et al (2017) Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: a population-based study. Oncotarget 8:44015\u201344031","journal-title":"Oncotarget"},{"key":"4144_CR4","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp R, Taillibert S, Kanner A et al (2017) Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318:2306\u20132316","journal-title":"JAMA"},{"key":"4144_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.critrevonc.2016.01.018","volume":"99","author":"K Seystahl","year":"2016","unstructured":"Seystahl K, Wick W, Weller M (2016) Therapeutic options in recurrent glioblastoma\u2013An update. Crit Rev Oncol Hematol 99:389\u2013408","journal-title":"Crit Rev Oncol Hematol"},{"key":"4144_CR6","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1016\/j.ejca.2012.04.011","volume":"48","author":"R Stupp","year":"2012","unstructured":"Stupp R, Wong ET, Kanner AA et al (2012) NovoTTF-100A versus physician\u2019s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer 48:2192\u20132202","journal-title":"Eur J Cancer"},{"key":"4144_CR7","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1200\/JCO.2021.39.15_suppl.2004","volume":"39","author":"P Roth","year":"2021","unstructured":"Roth P, Gorlia T, Reijneveld JC et al (2021) EORTC 1709\/CCTG CE.8: A phase III trial of marizomib in combination with temozolomide-based radiochemotherapy versus temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma. JCO 39:2004\u20132004","journal-title":"JCO"},{"key":"4144_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/neuonc\/nos273","volume":"15","author":"M Weller","year":"2013","unstructured":"Weller M, Cloughesy T, Perry JR et al (2013) Standards of care for treatment of recurrent glioblastoma\u2013are we there yet? Neuro Oncol 15:4\u201327","journal-title":"Neuro Oncol"},{"key":"4144_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s11060-016-2288-5","volume":"131","author":"MR Gilbert","year":"2017","unstructured":"Gilbert MR, Pugh SL, Aldape K et al (2017) NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma. J Neurooncol 131:193\u2013199","journal-title":"J Neurooncol"},{"key":"4144_CR10","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","volume":"377","author":"W Wick","year":"2017","unstructured":"Wick W, Gorlia T, Bendszus M et al (2017) Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med 377:1954\u20131963","journal-title":"N Engl J Med"},{"key":"4144_CR11","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1200\/JCO.2010.31.7107","volume":"29","author":"R Bagatell","year":"2011","unstructured":"Bagatell R, London WB, Wagner LM et al (2011) Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children\u2019s Oncology Group study. J Clin Oncol 29:208\u2013213","journal-title":"J Clin Oncol"},{"key":"4144_CR12","doi-asserted-by":"publisher","first-page":"vi186","DOI":"10.1093\/neuonc\/nox168.753","volume":"19","author":"A Levy","year":"2017","unstructured":"Levy A, Krailo M, Chi S et al (2017) PDCT-09. Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma\/cns pnet of childhood: report of a cog randomized phase ii screening trial. Neuro Oncol 19:vi186","journal-title":"Neuro Oncol"},{"key":"4144_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26448","author":"S Modak","year":"2017","unstructured":"Modak S, Kushner BH, Basu E et al (2017) Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: results of a phase II study. Pediatr Blood Cancer. https:\/\/doi.org\/10.1002\/pbc.26448","journal-title":"Pediatr Blood Cancer"},{"key":"4144_CR14","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1634\/theoncologist.2015-0135","volume":"20","author":"KB Peters","year":"2015","unstructured":"Peters KB, Lou E, Desjardins A et al (2015) Phase II trial of upfront bevacizumab, irinotecan, and temozolomide for unresectable glioblastoma. Oncologist 20:727\u2013728","journal-title":"Oncologist"},{"key":"4144_CR15","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.1158\/1078-0432.CCR-11-0120","volume":"17","author":"JJ Vredenburgh","year":"2011","unstructured":"Vredenburgh JJ, Desjardins A, Reardon DA et al (2011) The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res 17:4119\u20134124","journal-title":"Clin Cancer Res"},{"key":"4144_CR16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11060-015-2008-6","volume":"127","author":"TR Hummel","year":"2016","unstructured":"Hummel TR, Salloum R, Drissi R et al (2016) A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas. J Neurooncol 127:53\u201361","journal-title":"J Neurooncol"},{"key":"4144_CR17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3389\/fneur.2019.00042","volume":"10","author":"G Lu","year":"2019","unstructured":"Lu G, Rao M, Zhu P et al (2019) Triple-drug therapy with bevacizumab, irinotecan, and temozolomide plus tumor treating fields for recurrent glioblastoma: a retrospective study. Front Neurol 10:42","journal-title":"Front Neurol"},{"key":"4144_CR18","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00381-012-2013-4","volume":"29","author":"D Aguilera","year":"2013","unstructured":"Aguilera D, Mazewski C, Fangusaro J et al (2013) Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience. Childs Nerv Syst 29:589\u2013596","journal-title":"Childs Nerv Syst"},{"key":"4144_CR19","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1093\/ckj\/sfaa049","volume":"13","author":"M Shye","year":"2020","unstructured":"Shye M, Hanna RM, Patel SS et al (2020) Worsening proteinuria and renal function after intravitreal vascular endothelial growth factor blockade for diabetic proliferative retinopathy. Clin Kidney J 13:969\u2013980","journal-title":"Clin Kidney J"},{"key":"4144_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1023\/A:1006175831785","volume":"40","author":"JR Perry","year":"1998","unstructured":"Perry JR, Brown MT, Gockerman JP (1998) Acute leukemia following treatment of malignant glioma. J Neurooncol 40:39\u201346","journal-title":"J Neurooncol"},{"key":"4144_CR21","first-page":"8663","volume":"15","author":"P Liu","year":"2018","unstructured":"Liu P, Li P, Lei T et al (2018) Acute lymphoblastic leukemia following temozolomide treatment in a patient with glioblastoma: a case report and review of the literature. Oncol Lett 15:8663\u20138668","journal-title":"Oncol Lett"},{"key":"4144_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/BF00146880","volume":"10","author":"DL Silbergeld","year":"1991","unstructured":"Silbergeld DL, Rostomily RC, Alvord EC (1991) The cause of death in patients with glioblastoma is multifactorial: clinical factors and autopsy findings in 117 cases of supratentorial glioblastoma in adults. J Neurooncol 10:179\u2013185","journal-title":"J Neurooncol"},{"key":"4144_CR23","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2176\/nmc.43.375","volume":"43","author":"J Yoshimura","year":"2003","unstructured":"Yoshimura J, Onda K, Tanaka R et al (2003) Clinicopathological study of diffuse type brainstem gliomas: analysis of 40 autopsy cases. Neurol Med Chir (Tokyo) 43:375\u2013382","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"4144_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/bjc.2012.252","volume":"107","author":"B Penninckx","year":"2012","unstructured":"Penninckx B, Van de Voorde WM, Casado A et al (2012) A systemic review of toxic death in clinical oncology trials: an Achilles\u2019 heel in safety reporting revisited. Br J Cancer 107:1\u20136","journal-title":"Br J Cancer"},{"key":"4144_CR25","doi-asserted-by":"publisher","first-page":"E183","DOI":"10.1002\/ajh.24066","volume":"90","author":"TV Kourelis","year":"2015","unstructured":"Kourelis TV, Buckner JC, Gangat N et al (2015) Temozolomide induced bone marrow suppression\u2013A single institution outcome analysis and review of the literature. Am J Hematol 90:E183-184","journal-title":"Am J Hematol"},{"key":"4144_CR26","doi-asserted-by":"publisher","first-page":"E4","DOI":"10.3171\/2014.9.FOCUS14502","volume":"37","author":"GMV Barbagallo","year":"2014","unstructured":"Barbagallo GMV, Paratore S, Caltabiano R et al (2014) Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. Neurosurg Focus 37:E4","journal-title":"Neurosurg Focus"},{"key":"4144_CR27","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3892\/mco.2017.1160","volume":"6","author":"H Hirano","year":"2017","unstructured":"Hirano H, Kawahara T, Niiro M et al (2017) Anaplastic astrocytoma cells not detectable on autopsy following long-term temozolomide treatment: a case report. Mol Clin Oncol 6:321\u2013326","journal-title":"Mol Clin Oncol"},{"key":"4144_CR28","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.3892\/ijo.2014.2556","volume":"45","author":"R Tsunedomi","year":"2014","unstructured":"Tsunedomi R, Hazama S, Fujita Y et al (2014) A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes. Int J Oncol 45:1381\u20131390","journal-title":"Int J Oncol"},{"key":"4144_CR29","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1200\/JCO.2004.07.173","volume":"22","author":"F Innocenti","year":"2004","unstructured":"Innocenti F, Undevia SD, Iyer L et al (2004) Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382\u20131388","journal-title":"J Clin Oncol"},{"key":"4144_CR30","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1186\/s12885-017-3406-2","volume":"17","author":"D Liu","year":"2017","unstructured":"Liu D, Li J, Gao J et al (2017) Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis. BMC Cancer 17:437","journal-title":"BMC Cancer"},{"key":"4144_CR31","first-page":"37","volume":"32","author":"V Kushwaha","year":"2010","unstructured":"Kushwaha V, Yadav M, Srivastava A et al (2010) Time since death from degenerative changes in the Kidney. J Indian Acad Forensic Med 32:37\u201341","journal-title":"J Indian Acad Forensic Med"},{"key":"4144_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.legalmed.2003.09.001","volume":"6","author":"Y Tomita","year":"2004","unstructured":"Tomita Y, Nihira M, Ohno Y et al (2004) Ultrastructural changes during in situ early postmortem autolysis in kidney, pancreas, liver, heart and skeletal muscle of rats. Leg Med 6:25\u201331","journal-title":"Leg Med"},{"key":"4144_CR33","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/s41379-018-0186-4","volume":"32","author":"F Person","year":"2019","unstructured":"Person F, Rinschen MM, Brix SR et al (2019) Bevacizumab-associated glomerular microangiopathy. Mod Pathol 32:684\u2013700","journal-title":"Mod Pathol"},{"key":"4144_CR34","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/neuonc\/noz216","volume":"22","author":"MR Drumm","year":"2020","unstructured":"Drumm MR, Dixit KS, Grimm S et al (2020) Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas. Neuro Oncol 22:470\u2013479","journal-title":"Neuro Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-022-04144-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-022-04144-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-022-04144-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T09:08:23Z","timestamp":1667207303000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-022-04144-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["4144"],"URL":"https:\/\/doi.org\/10.1007\/s11060-022-04144-y","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"10 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study used postmortem human specimens and had reviewed medical records from deceased subjects. The study was performed in line with the principles of the Declaration of Helsinki. It is approved by the Health Sciences Institutional Review Board (IRB) at Tufts Medical Center. The same study protocol was also approved by the Committee for the Protection of Human Subjects (CPHS) at the University of Texas Health Science Center at Houston (UTHealth) (HSC-MS-11\u20130133).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"Consents for autopsy examination were obtained from all participants, either from patients when patients were alive or from the next of kin after subjects had deceased\u00a0before autopsy [full autopsies (N\u2009=\u200969), restricted autopsies to the brain (N\u2009=\u20096) and restricted to the brain and kidney (N\u2009=\u20091)].","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}